Kornimate/medical-research-clean huggingface dataset:
the efficacy of wet cupping therapy on cerebral oxygenation

Conditions: Cerebral Hypoxia

Summary: the aim of this clinical trial is to investigate the efficacy of wet cupping therapy (wct) on cerebral oxygenation using the nirs device. with the demonstration of the positive effect of the wct on cerebral oxygenation, it was aimed to use it effectively in stroke rehabilitation. in the outpatient clinic setting, firstly the sensor pads of the nirs device will be attached to the arcus superciliaris (gb14) under the tuber frontalis on both sides. after the measurement is initiated, wct will be applied to the planum occipitale (du 20) and to the pars squamosa (gb6-8) of the temporal bone on the sides. measurement will continue for 10 minutes during and after the wct application. nirs and oxygenation measurement data will be compared before, during, and after the wct application.

the importance of nirs is that it can detect differences in tissue oxygen uptake that cannot be routinely identified by existing methods (24). the ability of near-infrared (nir; near infrared; wavelength 650 - 1100nm) light to penetrate tissues and to be absorbed by some chromophores (such as haemoglobin, cytochrome oxidase, bilirubin, urobilin) has formed the basis of regional cerebral oxygen saturation (rsco2) measurement (15). nirs is a technique in which the amount of absorption of nir light by chromophore molecules \[such as oxyhaemoglobin (o2hb) and deoxyhaemoglobin (hhb), cytochrome-c oxidase (cco), myoglobin\] is measured while passing through tissues (16). rsco2 values less than 40% or changes greater than 25% from baseline values may be a harbinger of cerebral ischaemia (17). cerebral oximetry has attracted attention because it is easy to use and uncomplicated. nirs should be used as a trend monitor. in the current study, it is aimed to investigate the efficacy of wet cupping therapy (wct) on cerebral oxygenation using the nirs device. following the enrollment of the healthy individuals, they will all receive one session of wct. during the wct application, the cerebral oxygenation levels will be measured with an nirs device. in the outpatient clinic setting, the nirs device's sensor pads will be attached to the arcus superciliaris (gb14) under the tuber frontalis on both sides. after the measurement is initiated, wct will be applied to the planum occipitale (du 20) and the pars squamosa (gb6-8) of the temporal bone on the sides. measurement will continue for 10 minutes during and after the wct application. the data obtained by nirs will be compared before, during, and after the wct application so that we will be able to find out any possible effects of wct on cerebral oxygenation.

Eligibility criteria:
inclusion criteria: * healthy individual * age 18-65 years * consent to participate exclusion criteria: * having received cupping therapy in the past 3 months * contraindications for wct (such as hemoglobin level below 9.5 g/dl, bleeding disorders, receiving antithrombotic or antiplatelet therapy, inr value above 1.5), * coexisting chronic conditions and using any medication

Keywords: cerebral oxygenation wet cupping therapy nirs
effect of music during carotid endarterectomy

Conditions: Anxiety State

Summary: the purpose of this study is to test the hypothesis that music listening during carotid endarterectomy administered the cervical plexus block will cause less anxiety, less pain, and greater patient satisfaction.

patients who decided to participate in the study were randomized by means of a computer-generated randomization order into 2 groups: music group (group m) and operating room (or) noise group (group o). randomization was independently carried out in both centers. preoperative and postoperative state trait anxiety inventory (stai) scores, intraoperative stai responses, preoperative and postoperative numerical rating scale scores for anxiety, pain scores and hemodynamic parameters were recorded.

Eligibility criteria:
inclusion criteria: * patients undergoing carotid endarterectomy using cervical plexus block * american society of anesthesiologists class 2 to 3 * ability to consent exclusion criteria: * inability to communicate * not understand the aim and objectives of the study * not provide informed written consent * contraindications for the block (local infection, coagulation disorders) * hypersensitivity to the local anesthetics * refusal of regional anesthesia
prediction of preeclampsia (pe) at 11-13 week

Conditions: Pre-Eclampsia

Summary: this is an international multicentre prospective cohort study to validate the bayes theorem based algorithms for the screening of pre-eclampsia (pe) in the first-trimester of pregnancy.

the investigators have previously constructed bayes model in the first-trimester which combines maternal characteristics and medical history (mat-ch) together with mean arterial pressure (map), uterine artery pulsatility index (pi), and serum placental growth factor (plgf) with a plan to assess the predictive performance. the reference standards will be pe defined according to the international society for the study of hypertension in pregnancy and the american college of obstetricians and gynecologists. the systolic blood pressure should be \>140 mm hg and/or the diastolic blood pressure should be \>90 mmhg on at least two occasions four hours apart developing after 20 weeks' gestation in previously normotensive women and there should be proteinuria (\>300 mg in 24 hours or two readings of at \>2+ on dipstick analysis of midstream or catheter urine specimens if no 24-hour collection is available). in the absence of proteinuria, new onset of any of the following systemic findings: a) thrombocytopaenia (platelet counts \ 1.1 mg/dl or 2-fold increase in creatinine in the absence of underlying renal disease); c) abnormal liver function (ie, hepatic transaminase levels twice normal); d) pulmonary oedema; or e) cerebral or visual symptoms. preterm-pe is pe that requires delivery before 37 weeks' gestation. if a participant fulfills the criteria for pe by one definition and not the other she will be considered to have developed pe.

Eligibility criteria:
inclusion criteria: * aged ≥ 18 years * singleton pregnancy * live fetus * provide informed and written consent in the official language of the country exclusion criteria: * unable to provide written informed consent learning difficulties or serious mental illness or an inability to understand spoken and written the official language of the country. * multiple pregnancy * non-viable fetus (missed spontaneous abortion or stillbirth)

Keywords: bayes model
prevalence of the signs and symptoms of tmd in adolescents

Conditions: TMJ Disorder; TMD

Summary: the prevalence of the signs and symptoms of tempro-mandibular joint disorder in a sample of egyptian adolescents

our study is observational cross sectional study to evaluate the prevalence oftempro-mandibular joint disorder( tmds) in egyptian adolescents based on diagnostic criteria for tempro-mandibular disorders(dc/tmd) .the following examinationwill be done for each patient and recorded in his/her chart: include maximal mandibular opening capacity, joint noises, deviation of mandible during opening and closing, tenderness of the tmj and masticatory muscles, headache and pain in tmj area. all clinical examinations will be carried out by one investigator. examination of tmj disorders include the following aspects: i) examination of tmj sounds (clicking and crepitus) using a stethoscope over the tmj area and by having the patient open and close the mouth. ii) associated muscle disorders will be determined by: 1. palpation of tmj area. 2. digital palpation and functional manipulation of the masticatory muscles according to okeson.

Eligibility criteria:
inclusion criteria: * adolescents(age range10-18 years old). * a well-defined dentalcl i, cl ii/1, cl ii/2, and cl iii relationship (angle classification). * mixed and permanent dentition. * both sexes. * normal skeletal pattern exclusion criteria: * adolescents with syndromes. * systemic diseases affecting bones. * adolescents with rheumatoid arthritis. * previous trauma in the face. * neurological disorders. * psychiatric disorders. * neoplasia. * adolescents who had received orthodontic treatment.
the expression of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor in human trabecular meshwork

Conditions: Open-angle Glaucoma

Summary: this study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.the expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by hematoxylin and eosin staining.


Eligibility criteria:
inclusion criteria: * intraocular pressure greater than 22 mmhg with two or more medications * wide anterior chamber angle * glaucomatous optic neuropathy (glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect * visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry exclusion criteria: * the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc

Keywords: matrix metalloproteinase 13 tissue inhibitor of metalloproteinases 3 calcium-sensing receptor trabecular meshwork open-angle glaucoma
cobra (severe asthma)medical-economic

Conditions: Allergic Asthma

Summary: the severe asthma is a major source of expenses in term of public health, while it concerns no more than 5 % of the asthmatics. the expenses is direct (medicines, hospitalizations, care) but especially indirect (absenteeisms, etc.). the forward-looking follow-up of cohort of more than 500 severe asthmatic patients multicentrique in an already widely established cohort (cobra, at present in visit 9 (one every 6 months) is an once-in-a-lifetime opportunity, coupled with the data of the cpam, to identify well the evolution in time of a real medical economic variable. the possibility of dynamic follow-up of the expenses compared to the medical data offers perspectives of evaluation cost-efficiency of the informed therapeutic procedures. it is possible to couple in a forward-looking and dynamic way the data of health stemming from a cohort with the economic data stemming from the cpam. this variable included in a cluster's algorithm has to allow to identify the interventions the more and the less cost effective. the main objective of this study is to realize a cost estimate of care of the severe asthma. the variation of the costs will be also studied. the recruited patients are patients already included in the cohort cobra in the centers of marseille, montpelier or nice, classified gina 4 and agreeing to participate.

the following direct medical costs will be collected according to the point of view of the social security on a duration of 2 years: * hospitalizations (valuation from the ghs + medicines except ghs)· consultations (valuation am) * complementary(additional) examinations except hospitalization (valuation am) * pharmacy (valuation am) * transport (valuation am)the estimate of average costs will be made with a reliable interval for 95 %. the average cost by patient of the care will be calculated for every year of the follow-up. relationship individual cost-efficiency: by analogy with the studies cost-efficiency comparative clauses, the investigators shall calculate a relationship cost-efficiency at the individual level as follows: (cost-year2 - cost-year1) / (efficiency-year2 - efficiency-year 1). differences in these relationships will be looked for between various groups by tests of comparisons of averages.the construction of patients' clusters will be made according to the algorithm of the study sarp but also by using techniques statistics of classification non supervising to define our own algorithm. variables used on our algorithm will include the relationship cost efficiency individual in addition to the clinical variables. the temporal stability of the relationship cost efficiency will be analyzed. the risk factors of a modification of this relationship will be looked for.

Eligibility criteria:
inclusion criteria: * patients included in the observationnal cohort cobra for at least 6 months * patient members in one of the partner health insurance funds exclusion criteria: * the patient refusing his participation to the research

Keywords: severe asthma medical economic care cost efficiency cpam eq5d
the clinical trial of chidamide+decitabine+camrelizumab versus decitabine+camrelizumab in anti-pd-1 antibody resistant patients with classical hodgkin lymphoma.

Conditions: Hodgkin Lymphoma; Anti-PD-1 Antibody Resistant

Summary: this open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the orr obtained with chidamide+decitabine+camrelizumab against that obtained with decitabine+camrelizumab in patients with hodgkin lymphoma who were confirmed resistant to anti-pd-1 antibody therapy.


Eligibility criteria:
inclusion criteria: 1. subjects must have histological confirmation of relapsed or refractory hodgkin lymphoma (hl). 2. 12 to 75 years of age. 3. ecog performance of less than 2. 4. life expectancy of at least 3 months. 5. subjects with lymphoma must have at least one measureable lesion \>1 cm as defined by lymphoma response criteria. 6. subjects must have received anti-pd-1 antibody therapy and were confirmed anti-pd-1 antibody resistant. subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. 7. subjects must have adequate marrow, live, renal and heart functions. exclusion criteria: 1. subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. 2. serious uncontrolled medical disorders or active infections, pulmonary infection especially. 3. active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month. 4. prior organ allograft. 5. women who are pregnant or breastfeeding. 6. women with a positive pregnancy test on enrollment or prior to investigational product administration. 7. subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
non-invasive point-of-care diagnosis using machine learning and signal analytics to transform early detection of heart disease

Conditions: Coronary Artery Disease

Summary: this study is designed as a repository study to collect resting cardiac phase signals and subject meta data from eligible subjects using the phase signal recorder (psr) prior to coronary angiography. the repository data will be used for the purposes of research, development, optimization and testing of machine-learning algorithms developed by analytics 4 life.

male and female subjects will be uniquely and consecutively enrolled into one of two groups to support populating a repository of phase signals: group 1: subjects with known prior coronary artery disease or previous percutaneous coronary intervention (pci), and group 2: subjects with new onset symptoms suggestive of obstructive coronary artery disease at current presentation with no known coronary artery disease. enrollment into group 1 and group 2 will occur simultaneously until up to 500 male subjects and up to 1000 female subjects with paired data (phase signal and coronary angiography outcomes data) are enrolled. once the desired number of subjects have been enrolled from both groups, then only group 2 will continue to be enrolled. resting phase signals will be collected in all patients who meet inclusion/exclusion criteria and have signed an informed consent form. this study consists of a screening visit, resting phase signal collection (study procedure), and coronary angiography. in this study, resting phase signals will be acquired in subjects prior to coronary angiography.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years old; 2. symptoms suggestive of obstructive cad; 3. scheduled to undergo cardiac catheterization with coronary angiography; 4. ability to understand the requirements of the study and to provide written informed consent. exclusion criteria: 1. prior documented history of myocardial infarction (mi); 2. suspected acute myocardial infarction (ami) at current presentation; 3. prior coronary artery bypass grafting (cabg); 4. prior heart valve replacement; 5. previous sustained or paroxysmal atrial or ventricular arrythmia; 6. infiltrative myocardial disease (amyloid, sarcoid, right ventricular dysplasia); 7. presence of cardiac implantable electronic device (cied), including implantable cardioverter defibrillator (icd), pacemaker (pm), implantable loop recorders and other monitors; 8. implantable neuro-stimulators; 9. congenital heart disease; 10. pregnant or breast feeding; 11. currently taking any type ia, ic or iii antiarrhythmics; 12. any history of amiodarone use; 13. clinically significant chest deformity (e.g., pectus excavatum or pectus carinatum); 14. breast implants; 15. neuromuscular disease if the condition results in tremor or muscle fasciculations.

Keywords: coronary angiography coronary artery disease
does the aid of melafind affect clinical management decisions

Conditions: Melanoma

Summary: the objective of this study is to determine and compare the performance of dermatologists (in germany) on the excision decision against the performance of melafind, a non-invasive and objective multi-spectral computer vision system designed as a tool to aid dermatologists in the detection of early melanoma. the hypothesis is that melafind's sensitivity is superior to the average excisions sensitivity of dermatologists. another objective is to determine and compare the performance of dermatologists (in germany) with and without the aid of melafind. the hypothesis is that the average excision sensitivity of dermatologists with the aid of melafind is superior to the average excision sensitivity of dermatologists without the aid of melafind. a similar study was previously conducted with dermatologists in the us (nct01011153). an exploratory objective is to compare the excision decisions of dermatologists from the previous study (in the us) to dermatologists in in this study (in germany).

early detection of melanoma is critical for favorable prognosis, since patients with earlier stage melanomas have a much higher probability of survival than with later stages. the traditional method of early detection has been with serial total body skin exams where the health care provider examines all skin surfaces, including mucosa, for suspicious pigmented lesions. the diagnostic performance of dermatologists for melanoma depends on the level of dermatological training. more important than being able to make a diagnosis of melanoma on clinical impression is the ability to make an appropriate decision to excise the lesion. to aid dermatologists in the detection of early melanoma, melafind was developed, a non-invasive and objective multi-spectral computer vision system technology. it was designed to generate output - melafind positive or melafind negative- for consideration in the lesion management decisions. this survey study will determine and compare the average excision sensitivity to melanoma and specificity of dermatologists (in germany) without melafind output to the average excision sensitivity to melanoma and specificity of dermatologists (in germany) with melafind output. another purpose is to determine and compare the sensitivity to melanoma and specificity of melafind to the average excision sensitivity to melanoma and specificity of dermatologists without melafind output.

Eligibility criteria:
inclusion criteria: -only board certified dermatologists exclusion criteria: -may not have previously participated in mela protocols 20061, 20081 or 20063
study to learn more about the benefits and side-effects of drugs rivaroxaban and apixaban compared to the drug warfarin for stroke prevention in patients with rapid and irregular heartbeat which is not due to a heart-valve fault (non-valvular atrial fibrillation) in the uk routine clinical practice

Conditions: Atrial Fibrillation

Summary: this population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as treatment for stroke prevention in atrial fibrillation (spaf). purpose of the study is to learn more about the safety and how well the drugs rivaroxaban, apixaban and warfarin work in patients appropriately and inappropriately receiving standard and reduced doses of each drug for reducing the risk of stroke in atrial fibrillation. real world data from routine general practice stored in the primary care database in the uk, the health improvement network (thin), will be used for investigation.

primary objectives are to assess the safety and effectiveness of rivaroxaban, apixaban and warfarin based on the risk of intracranial hemorrhage and hemorrhagic strokes (safety) and ischemic stroke, systemic embolism and myocardial infarction (effectiveness). secondary objectives comprise the assessment of the mentioned risks in subpopulations of patients with renal impairment or diabetes, mortality rates, and drug utilisation as well as patient characteristics before and after the first intracranial hemorrhage or ischemic stroke.

Eligibility criteria:
inclusion criteria: * patients with non-valvular atrial fibrillation * new users of rivaroxaban, apixaban or warfarin * at least one year enrollment with the general practice (gp) * one year since first health contact recorded in thin prior to the first prescription of a study drug exclusion criteria: * patients with other recent indications of oral anticoagulant initiation * individuals on more than one oral anticoagulant on the start date * users of rivaroxaban apart from 15 / 20 mg daily dose * users of apixaban apart from 5 / 10 mg daily dose

Keywords: oral anticoagulants under-dosing stroke prevention in atrial fibrillation safety effectiveness